PMID- 26264462
OWN - NLM
STAT- MEDLINE
DCOM- 20160317
LR  - 20181113
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 13
DP  - 2015 Aug 12
TI  - Expression of miR-296-5p as predictive marker for radiotherapy resistance in 
      early-stage laryngeal carcinoma.
PG  - 262
LID - 10.1186/s12967-015-0621-y [doi]
LID - 262
AB  - PURPOSE: Definitive radiation therapy is the mainstay of treatment for early 
      stage laryngeal squamous cell carcinoma (LSCC). However, up to 30% of the 
      patients do not respond to radiotherapy. Unfortunately, we are unable to predict 
      which tumors are likely to respond to radiation, and which will be resistant and 
      persist. Therefore, the development of novel markers to predict response to 
      radiotherapy is urgently needed. This study was designed to evaluate the 
      expression pattern of microRNAs (miRNAs) in LSCC in order to identify markers 
      capable of segregating radioresistant and radiosensitive tumors and to 
      investigate the relationship between the expression of these miRNAs and the 
      prognosis of LSCC. METHODS: The expression profile of 667 miRNAs was determined 
      in an initial screening of nine early-stage LSCC samples (5 radioresistant and 4 
      radiosensitive) using TaqMan Low-Density Array (TLDA). Real-time polymerase chain 
      reactions were performed to validate the expression of selected miRNAs in an 
      expanded LSCC cohort (20 radioresistant and 14 radiosensitive). The miRNA 
      expression level was scored as high or low based on the median of the expression 
      in the LSCC samples. RESULTS: A comprehensive miRNA expression profiling enabled 
      the identification of four miRNAs (miR-296-5p miR-452, miR-183* and miR-200c) 
      differentially expressed in radioresistant LSCC. Moreover, the analysis of 
      additional 34 LSCC samples, confirmed the expression of miR-296-5p as 
      significantly related to radioresistance (p = 0.002) as well as an association of 
      this marker with recurrence (p = 0.025) in early stage laryngeal cancer. 
      CONCLUSIONS: This study indicates that miR-296-5p expression is associated with 
      resistance to radiotherapy and tumor recurrence in early stage LSCC, showing the 
      feasibility of this marker as a novel prognostic factor for this malignance. 
      Furthermore, miR-296-5p expression could be helpful in the identification of 
      tumors resistant to radiotherapy; thus aiding the clinicians in the choice of the 
      best therapeutic scheme to be used in each case.
FAU - Maia, Danielle
AU  - Maia D
AD  - Laboratory of Molecular Cancer Biology, Department of Biological Sciences, 
      Federal University of Sao Paulo, Rua Pedro de Toledo, 669-11 degrees  andar, Sao Paulo, 
      SP, 04039-032, Brazil. dellymaia@gmail.com.
FAU - de Carvalho, Ana Carolina
AU  - de Carvalho AC
AD  - Laboratory of Molecular Cancer Biology, Department of Biological Sciences, 
      Federal University of Sao Paulo, Rua Pedro de Toledo, 669-11 degrees  andar, Sao Paulo, 
      SP, 04039-032, Brazil. ca_oak@yahoo.com.br.
AD  - Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte 
      Vilela, 1331, Barretos, SP, 14784-400, Brazil. ca_oak@yahoo.com.br.
FAU - Horst, Maria Aderuza
AU  - Horst MA
AD  - Laboratory of Molecular Cancer Biology, Department of Biological Sciences, 
      Federal University of Sao Paulo, Rua Pedro de Toledo, 669-11 degrees  andar, Sao Paulo, 
      SP, 04039-032, Brazil. aderuza@gmail.com.
FAU - Carvalho, Andre Lopes
AU  - Carvalho AL
AD  - Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte 
      Vilela, 1331, Barretos, SP, 14784-400, Brazil. alopescarvalho@uol.com.br.
AD  - Department of Head and Neck Surgery, Barretos Cancer Hospital, Rua Antenor Duarte 
      Villela, 1331, Barretos, 14784-400, Brazil. alopescarvalho@uol.com.br.
FAU - Scapulatempo-Neto, Cristovam
AU  - Scapulatempo-Neto C
AD  - Department of Pathology, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 
      1331, Barretos, 14784-400, Brazil. cristovamscapula@uol.com.br.
FAU - Vettore, Andre Luiz
AU  - Vettore AL
AD  - Laboratory of Molecular Cancer Biology, Department of Biological Sciences, 
      Federal University of Sao Paulo, Rua Pedro de Toledo, 669-11 degrees  andar, Sao Paulo, 
      SP, 04039-032, Brazil. andre.vettore@gmail.com.
AD  - Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, 
      Singapore, Singapore. andre.vettore@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150812
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN296 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Female
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology/*radiotherapy
MH  - Male
MH  - MicroRNAs/*genetics/metabolism
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms, Squamous Cell/genetics/pathology/radiotherapy
MH  - Prognosis
MH  - Radiation Tolerance/*genetics
MH  - Survival Analysis
PMC - PMC4533949
EDAT- 2015/08/13 06:00
MHDA- 2016/03/18 06:00
PMCR- 2015/08/12
CRDT- 2015/08/13 06:00
PHST- 2015/03/08 00:00 [received]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2016/03/18 06:00 [medline]
PHST- 2015/08/12 00:00 [pmc-release]
AID - 10.1186/s12967-015-0621-y [pii]
AID - 621 [pii]
AID - 10.1186/s12967-015-0621-y [doi]
PST - epublish
SO  - J Transl Med. 2015 Aug 12;13:262. doi: 10.1186/s12967-015-0621-y.